(Total Views: 641)
Posted On: 08/18/2020 8:06:32 PM
Post# of 153887
“Love this answer, because you are exactly right. We have enough money now to do whatever we want for trials.”
Unfortunately this isn’t 100% accurate. Yes, CYDY has more cash the they have ever had, but trials take time to complete, sometimes years, and that process is expensive. Clinical trial costs combined with operational costs (NP’s Nice salary and paid advertisements) add up. IMO, NP needs to focus cash expenditures on finishing the HIV BLA, increasing cancer enrollment sites, getting the GvHD trial on par, and begin the NASH trial. Those 4 indications alone are going to be expensive and take months to years to complete. I believe NP’s ambition to start 10 (?) more trials by the end of the year was over zealous and didn’t account for the BLA delay, drop in SP and drawn on results from COVID. He needs to rethink the plan and shoot for the immediate targets that could result in approval, BTD, and/or a partnership.
Unfortunately this isn’t 100% accurate. Yes, CYDY has more cash the they have ever had, but trials take time to complete, sometimes years, and that process is expensive. Clinical trial costs combined with operational costs (NP’s Nice salary and paid advertisements) add up. IMO, NP needs to focus cash expenditures on finishing the HIV BLA, increasing cancer enrollment sites, getting the GvHD trial on par, and begin the NASH trial. Those 4 indications alone are going to be expensive and take months to years to complete. I believe NP’s ambition to start 10 (?) more trials by the end of the year was over zealous and didn’t account for the BLA delay, drop in SP and drawn on results from COVID. He needs to rethink the plan and shoot for the immediate targets that could result in approval, BTD, and/or a partnership.
(2)
(0)
